CORRECTING AND REPLACING/Gilead Sciences Receives Subpoena from
U.S. Department of Justice
FOSTER CITY, Calif.--(BUSINESS WIRE)--June 10, 2011--
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has
received a subpoena from the United States Attorney's Office for
the Northern District of California requesting documents related to
the manufacture, and related quality and distribution practices, of
Atripla(R) , Emtriva(R) , Hepsera(R) , Letairis(R) , Truvada(R) ,
Viread(R) and our investigational fixed-dose combination of Truvada
and Edurant(TM) . Gilead is cooperating in this civil and criminal
investigation.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company's mission is to advance the care of
patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Asia Pacific.
Emtriva, Hepsera, Letairis, Truvada and Viread are registered
trademarks of Gilead Sciences, Inc. Atripla is a registered
trademark of Bristol-Myers Squibb & Gilead Sciences, LLC.
Edurant is a trademark of Tibotec Pharmaceuticals.
For more information on Gilead Sciences, please visit the
company's website at www.gilead.com or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
CONTACT: Gilead Sciences, Inc.
Patrick O'Brien, 650-522-1936 (Investors)
Cara
Miller, 650-522-1616 (Media)
SOURCE: Gilead Sciences, Inc.
Copyright Business Wire 2011